BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 4, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 22, 1999
View Archived Issues
Maxim allowed additional U.S. patent for Maxamine technology
Read More
FDA clears Uni-Gold Strep A test
Read More
Copernicus Therapeutics receives grant from NCI for novel gene therapy research
Read More
Angstrom and Diatide to develop new cancer treatments and diagnostic products
Read More
First clinical experiences reported with S-1197 and its orally active prodrugs
Read More
Cholesterol biosynthesis inhibitors in the Zeneca pipeline
Read More
Aastrom receives SBIR grant for cord blood transplant program
Read More
Agents for disorders of GABAergic transmission from Synthelabo
Read More
James Black Foundation describes new H3 ligands
Read More
Heterocyclic compounds with antitumor activity developed at Zenyaku Kogyo
Read More
News from ASCPT: first report of clinical evaluation of Schwarz's organic nitrate
Read More
Endothelin receptor antagonists for cardiovascular, renal and cerebral disorders
Read More
Hungarian research team describes GnRH receptor-targeted antitumor drug conjugates
Read More
Amgen patents novel hydroxamic acid-based MMP inhibitors
Read More
Novel tacrolimus (FK-506) prodrug expected to have superior therapeutic activity
Read More
Ono-4057: BLT receptor antagonist with beneficial effects in rat model of nephritis
Read More
Profile of CS-747, a novel antiplatelet agent from Sankyo and Ube
Read More
Design and synthesis of new CRF1 antagonist NBI-30545 presented at ACS meeting
Read More
Enrollment completed in phase III LeuTech clinical trial
Read More
Three products advance in the pipeline at Chugai
Read More
ACS highlights: Agouron and Roche present MMP inhibitor clinical candidate
Read More
FDA approves first product specifically for pain associated with postherpetic neuralgia
Read More
German launch announced for Novartis immunosuppressant
Read More
Potent, orally active CRF antagonist with anxiolytic activity reported by DuPont at ACS meeting
Read More
Gilead initiates phase III trial of adefovir dipivoxil in treatment of HBV
Read More
Compounds emerging from Neurocrine Biosciences' CRF antagonist program
Read More
Digene's DNA-based HPV test cleared for U.S. marketing
Read More
Scotia's photodynamic cancer drug receives fast track status from FDA
Read More
Synaptic updates migraine program
Read More
